Sun Pharma Industries reported a sequential decline of 19% in profit after tax (PAT) for the fourth quarter of FY26, amounting to Rs 2,714 crore. The revenue for the quarter also saw a 6% decrease from the previous quarter, totaling Rs 15,520 crore. Despite these declines, the board has approved a final dividend of Rs 5 per equity share, pending shareholder approval at the upcoming 34th Annual General Meeting.
The company's Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) for the quarter stood at Rs 3,954 crore, marking a 6.4% year-on-year increase. The EBITDA margin was reported at 27.1%. In its exchange filing, Sun Pharma highlighted a 20% rise in global innovative medicines sales, reaching $354 million and contributing 22.2% to overall sales.
For the full fiscal year FY26, Sun Pharma demonstrated strong consolidated performance with a 12.9% year-on-year increase in revenue from operations, reaching Rs 58,220 crore. The Global Innovative Medicines segment was a significant growth driver, with sales of $1.42 billion, excluding milestone income, showing a robust 16.4% growth and contributing 20.7% to total sales.
The pharmaceutical giant reported a 16% year-on-year increase in EBITDA for FY26, amounting to Rs 17,731 crore, with an improved EBITDA margin of 30.3%. Net profit for the year was Rs 11,479 crore, a 5% increase over the previous year, despite ongoing investments in expansion and research.
Sun Pharma invested Rs 3,554 crore in research and development during FY26, representing 6.1% of total sales, underscoring its commitment to innovation and growth in specialty and differentiated products.
Background
Sun Pharma's performance in FY26 highlights its strategic focus on expanding its innovative medicines portfolio, which has been a key driver of growth. The company's ongoing investment in research and development is expected to continue supporting its long-term growth strategy.
Looking ahead, Sun Pharma's focus on specialty and differentiated products, along with its robust R&D investments, positions it well for sustained growth. Investors will be keenly watching the company's strategic initiatives and market performance in the upcoming quarters.
